Clinical vignette

Nuclear Medicine Review 2022, 25, 2: 136–137

DOI: 10.5603/NMR.a2022.0030

Copyright © 2022 Via Medica

ISSN 1506–9680, e-ISSN 1644–4345

Amino acid extravasation: a rare red flag to keep in mind during peptide receptor radioligand therapy (PRRT) with [177Lu]Lu-DOTATATE

Ghasemali Divband1Seyed Hootan Alavi2Zohre Adinehpour3Forough Kalantari4Soroush Zarehparvar Moghadam5
1Nuclear Medicine Center, Jam Hospital, Tehran, Iran
2Department of Surgery, Khatam-al-Anbia Hospital, Tehran, Iran
3Khatam PET/CT center, Khatam-al-Anbia Hospital, Tehran, Iran
4Department of Nuclear Medicine, Hazrat-e-Rasool General Hospital, Iran University of Medical Sciences, Tehran, Iran
5Nuclear Medicine Center, Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, Iran

[Received 11 I 2022; Accepted 27 IV 2022]

This article is available in open access under Creative Commo

Correspondence to: Soroush Zarehparvar Moghadam, Nuclear Medicine Department, Velayat hospital, Qazvin, Iranphone: +98 2833792144, e-mail: sorooshzm@gmail.com

n Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

A 64 years-old woman with intestinal neuroendocrine tumor (NET) and multiple liver metastases was referred for peptide receptor radioligand therapy (PRRT) with [177Lu]Lu-DOTATATE. A few days after the third cycle of PRRT, erythema and swelling in the injection site is occurred which progressed up to one-month post-therapy. The cutaneous lesion was managed by a plastic surgeon with topical treatment. Amino acid extravasation could have devastating effects and should always be considered in patients who underwent PRRT and who receive amino acids for nephroprotection.
KEY words: NET; PRRT; cutaneous; extravasation; [177Lu]Lu-DOTATATE
Nucl Med Rev 2022; 25, 2: 136–137

A 64 years-old woman with intestinal neuroendocrine tumor (NET) and multiple progressive liver metastases underwent 3 cycles of peptide receptor radioligand therapy (PRRT) with [177Lu]Lu-DOTATATE. She had only received long-acting somatostatin analogs before. After two cycles of PRRT, the patient had a stable disease. In the third course of PRRT, 6.3 GBq [177Lu]Lu-DOTATATE was injected thirty minutes after starting the infusion of the amino acid solution (25 g lysine and 25 arginine diluted with 2000 cc normal saline during 6 hours). Like previous treatment courses, a three-way valve catheter was inserted in the right antecubital fossa to administer amino acids and [177Lu]Lu-DOTATATE via the same venous access. The patient did not report any discomfort or side effects; while blood pressure and pulse rate monitoring was performed throughout the treatment period. The -post-therapy whole-body scan was performed after 24 hours using the Siemens Symbia Intevo SPECT/CT dual-head gamma camera with a matrix size of 1024 × 256 and speed of 10 cm/min and showed a primary tumor in the small intestine with intense [177Lu]Lu-DOTATATE uptake as well as several [177Lu]Lu-DOTATATE avid metastases throughout the liver (Fig. 1).

D_1.jpg
Figure 1. Post therapy whole body [177Lu]Lu-DOTATATE scan performed 24 hours after therapy

Three days after the therapy the patient felt a burning sensation in the injection site with erythema and tenderness which deteriorates up to one month after PRRT at the time the patient informed us about this problem (Fig. 2). The post-therapy [177Lu]Lu-DOTATATE whole-body scan was reviewed again and only a minimal focus of [177Lu]Lu-DOTATATE extravasation was noted in the right antecubital fossa which could not be the cause of the large skin lesion.

D_2.jpg
Figure 2. The lesion is an erythematous and erosive plaque with a sharp margin in the anterior cubital fold of the right hand with some degrees of secretion

The patient was referred to a plastic surgeon and topical therapies were administered and the skin lesion healed within four months (Fig. 3). We concluded that since there was no sign of [177Lu]Lu-DOTATATE extravasation on post-therapy whole-body scan, this side effect is most likely due to the amino acid extravasation. Due to the high osmolarity of the Amino acid solution, its extravasation could cause serious cutaneous damages, even tissue necrosis which may need tissue debridement. This case shows the importance of monitoring the patient during the PRRT course and especially early physical examinations during the course of therapy and in the first week after to evaluate any adverse events that may occur to the patient.

8428.png

Conflict of interest

The authors declare no conflict of interest.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl